Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own0.10% Shs Outstand195.92M Perf Week-7.48%
Market Cap1.07B Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float180.91M Perf Month42.41%
Income-229.10M PEG- EPS next Q-0.21 Inst Own62.00% Short Float26.99% Perf Quarter92.23%
Sales29.60M P/S36.01 EPS this Y-3.80% Inst Trans0.12% Short Ratio9.02 Perf Half Y216.28%
Book/sh-0.75 P/B- EPS next Y20.00% ROA-63.90% Target Price5.89 Perf Year29.83%
Cash/sh0.58 P/C9.40 EPS next 5Y- ROE289.30% 52W Range1.26 - 6.38 Perf YTD277.78%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-90.80% 52W High-14.73% Beta2.78
Dividend %- Quick Ratio2.10 Sales past 5Y-30.20% Gross Margin91.60% 52W Low331.75% ATR0.40
Employees98 Current Ratio2.10 Sales Q/Q91.80% Oper. Margin- RSI (14)66.19 Volatility9.62% 6.78%
OptionableYes Debt/Eq- EPS Q/Q53.80% Profit Margin- Rel Volume1.22 Prev Close5.59
ShortableYes LT Debt/Eq- EarningsJul 30 AMC Payout- Avg Volume5.41M Price5.44
Recom2.60 SMA2029.25% SMA5045.23% SMA200112.64% Volume6,601,330 Change-2.68%
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Aug-14-08Initiated Banc of America Sec Neutral $7
Aug-06-08Reiterated Lazard Capital Buy $12 → $10
Aug-06-08Downgrade Canaccord Adams Buy → Hold
Jul-08-08Initiated Canaccord Adams Buy $7.30
Dec-07-07Reiterated Fortis Bank Hold $10 → $9
Sep-14-07Initiated Lazard Capital Buy $14
Jul-27-15 03:43PM  Exelixis (EXEL) Stock Falls on Upsized Secondary Offering at TheStreet
Jul-26-15 08:54AM  3 Biotech Stocks That Could Double Before 2016 at Motley Fool
Jul-24-15 04:39PM  EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:45PM  How to Trade 4 of the Market's Most Active Stocks at TheStreet
Jul-23-15 08:08PM  Exelixis Prices Public Offering of Common Stock Business Wire -6.81%
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
Jul-22-15 10:52AM  Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
09:54AM  Exelixis (EXEL) Stock Declines on Secondary Public Offering at TheStreet
Jul-21-15 06:40PM  Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
05:29PM  How Exelixis Used Good News to Raise Over $100 Million in New Capital at 24/7 Wall St.
04:01PM  Exelixis Launches Proposed Public Offering of Common Stock Business Wire
08:05AM  Potential Kidney Cancer Drugs Could Revolutionize Treatment at Motley Fool
04:51AM  Novartis bullish on Afinitor cancer drug despite new competition
Jul-20-15 05:24PM  EXELIXIS, INC. Files SEC form 8-K, Other Events +50.38%
04:11PM  Exelixis, Inc. (EXEL) Soars Following Cancer Drug Trial Data, But Competition Looms at Insider Monkey
02:33PM  Exelixis' Meteroric Rise From the Ashes at Motley Fool
12:03PM  Market Update: Monday's Mid-Day Movers; Greece Opens Banks; Gold Dwindles
10:50AM  Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer at Investor's Business Daily
10:35AM  Is Exelixis a Buyout Target Again? at 24/7 Wall St.
10:31AM  Why Exelixis, Inc.'s Stock Skyrocketed Today at Motley Fool
10:18AM  Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley Beats Q2 Views
09:38AM  Exelixis Up 50% After Meteroric METEOR Results
09:00AM  Exelixis shares surge 47% as kidney cancer drug trial yields positive results at MarketWatch
08:30AM  Exelixis Inc Conference Call to discuss the Results of Clinical Trial scheduled for 8:30 am ET today
07:02AM  Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech at Forbes
07:01AM  Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales at TheStreet
07:00AM  Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma Business Wire
Jul-16-15 06:50PM  Chart Week! Copper & gold +5.74%
09:01AM  3 Biotech Stocks 50% (or More) Off Their 5-Year Highs That Could Double at Motley Fool
06:02AM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
01:32AM  Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer Business Wire
Jul-14-15 04:30PM  Exelixis' Cabozantinib in Phase I for Genitourinary Cancers - Analyst Blog
Jul-13-15 08:30AM  Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Business Wire
Jul-05-15 10:01AM  Exelixis to Investors: "Wait for It... No, Seriously, Wait for It!" at Motley Fool
Jul-02-15 04:00PM  Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog
Jul-01-15 06:21PM  Why Exelixis, Inc. Shares Slumped Today at Motley Fool -7.18%
11:23AM  10 Best Biotech Stocks in the NASDAQ at TheStreet
09:17AM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat
08:45AM  Exelixis Provides Update on Genentechs Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound Business Wire
Jun-30-15 12:02PM  Small Cap Stocks to Watch in Biotech at Motley Fool +6.21%
Jun-26-15 06:01AM  Biotech Stock Mailbag: Exelixis, Puma Bio at TheStreet
Jun-25-15 10:30AM  5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Jun-22-15 09:32AM  Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape
Jun-20-15 11:31AM  Watch These 10 Stocks Over The Weekend
Jun-07-15 09:10AM  How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer at 24/7 Wall St.
Jun-06-15 12:21AM  ASCO Reaffirms Why I'm Holding Exelixis at Investopedia
Jun-01-15 02:06PM  Cancer drugmakers rally on upbeat prognosis at Financial Times +9.21%
12:31PM  Notable option activity in equities
09:40AM  6 Key Cancer Winners From ASCO Presentations at 24/7 Wall St.
May-31-15 09:00AM  Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer Business Wire
09:00AM  Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged Non-Small Cell Lung Cancers Business Wire
May-30-15 07:30AM  Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting Business Wire
May-28-15 04:37PM  EXELIXIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-22-15 06:42PM  5 Things Exelixis Management Wants You to Know at Investopedia
May-13-15 01:37PM  6 stocks to watch at MarketWatch
May-11-15 09:25AM  Exelixis (EXEL) Worth Watching: Stock Moves 10.3% Higher - Tale of the Tape
May-08-15 04:29PM  Exelixis (EXEL) Stock Spikes on First Quarter Earnings Report at TheStreet +10.29%
May-04-15 07:00PM  How 42 Words Completely Changed Exelixis' Report at Investopedia
06:24PM  Exelixis to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 12 at noodls
04:05PM  Exelixis to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 12 Business Wire
Apr-30-15 06:45PM  Exelixis reports 1Q loss -6.20%
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:47PM  Exelixis Announces First Quarter 2015 Financial Results and Provides Corporate Update at noodls
04:25PM  Cabozantinib and Cobimetinib to Be Featured in Fourteen Presentations at 2015 ASCO Annual Meeting Business Wire
04:23PM  Exelixis Announces First Quarter 2015 Financial Results and Provides Corporate Update Business Wire
04:05PM  EXELIXIS, INC. Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities
07:07AM  Q1 2015 Exelixis Inc Earnings Release - After Market Close
Apr-29-15 05:14PM  Will Endocyte (ECYT) Disappoint This Earnings Season? - Analyst Blog
04:24PM  Is Exelixis (EXEL) Likely to Report Narrower Loss in Q1? - Analyst Blog
Apr-28-15 03:17PM  Will Vertex (VRTX) Surprise with a Lower Loss in Q1? - Analyst Blog
02:31PM  Will AmerisourceBergen (ABC) Beat on Earnings Yet Again? - Analyst Blog
Apr-27-15 02:40PM  Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog -8.12%
Apr-21-15 02:39PM  Biotech Investors: May 29th Could Be A Big Day
Apr-20-15 10:22AM  Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape
09:30AM  The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners - Press Releases
08:52AM  Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape
Apr-17-15 11:57AM  3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog
Apr-16-15 10:30AM  Exelexis (EXEL) Is The 'Chart of the Day' at TheStreet
Apr-13-15 08:14AM  Bulls can't get enough of Exelixis
Apr-10-15 04:49PM  Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog
Apr-09-15 05:38PM  Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 at noodls +5.61%
05:05PM  Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Business Wire
02:32PM  Exelixis (EXEL) Stock Rises Today Following FDA Fast Track Designation at TheStreet
09:17AM  Exelixis Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma at noodls
08:30AM  Exelixis Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma Business Wire
Apr-01-15 06:00AM  Roche open to alliances in hunt for cancer drug combinations Reuters
Mar-30-15 07:16PM  Cramer Remix: In all my years, never seen this! at CNBC +6.30%
05:13PM  3 (Rough) Dates Exelixis Shareholders Need to Know at Investopedia
Mar-25-15 05:00PM  Biotech in nice uptrend: Adami -6.20%
Mar-18-15 08:45AM  Is Exelixis (EXEL) Stock a Solid Choice Right Now? - Tale of the Tape
Mar-11-15 05:33PM  GSK's big bet: Tapping our body's electronics at CNBC
12:04PM  18 Biotech Stocks These Wall Street Analysts Are Tracking
Mar-10-15 01:04PM  EXELIXIS, INC. Financials
Mar-09-15 04:11PM  EXELIXIS, INC. Files SEC form 8-K, Other Events
Mar-06-15 09:42PM  Exelixis to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3 at noodls
09:42PM  Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update at noodls
06:00PM  Is Exelixis Under-the-Radar Growth? at Investopedia
Mar-02-15 05:17PM  EXELIXIS, INC. Files SEC form 10-K, Annual Report +5.46%
Feb-27-15 09:29AM  Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape
Feb-26-15 04:05PM  Exelixis to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3 Business Wire +8.92%
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaEVP and Chief Medical OfficerNov 15Option Exercise0.003,125078,730Nov 18 06:57 PM
Lamb PeterEVP, Discovery Research & CSONov 15Option Exercise0.002,083037,237Nov 18 06:55 PM
BURKE DEBORAHSVP & Chief Financial OfficerNov 15Option Exercise0.006,438019,377Nov 18 06:52 PM
MARCHESI VINCENT TDirectorSep 17Buy1.7120,00034,19945,000Sep 19 05:05 PM